Skip to main content
Premium Trial:

Request an Annual Quote

TGen to Participate in DoD Program Studying Pharmacogenomics of Breast Cancer

NEW YORK (GenomeWeb News) – The Translational Genomics Reserach Institute will play a "primary" role in a $10.7-million Department of Defense breast cancer research program, the nonprofit said yesterday.
The multi-institutional, five-year research program is led by Philadelphia’s Fox Chase Cancer Center. The grant focuses on developing a new treatment model for breast cancer to reverse resistance to anti-estrogen therapy.
TGen will collaborate with FCCC and Georgetown University to map the genetic and biological events associated with breast tumor cells and analyze the results to identify patterns consistent with resistance to various anti-hormone therapies.
A Johns Hopkins University team will evaluate the patterns under phase I and II clinical studies.
The ultimate goal of the study is to exploit the knowledge of measurable similarities shared by drug-resistant breast cancers and translate that knowledge into more accurate prognostic tests and pharmacogenomic treatments.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.